title: Single nucleotide polymorphisms in microRNA binding sites of oncogenes: implications in cancer and pharmacogenomics.
abstract: Cancer, a complex genetic disease involving uncontrolled cell proliferation, is caused by inactivation of tumor suppressor genes and activation of oncogenes. A vast majority of these cancer causing genes are known targets of microRNAs (miRNAs) that bind to complementary sequences in 3' untranslated regions (UTR) of messenger RNAs and repress them from translation. Single Nucleotide Polymorphisms (SNPs) occurring naturally in such miRNA binding regions can alter the miRNA:mRNA interaction and can significantly affect gene expression. We hypothesized that 3'UTR SNPs in miRNA binding sites of proto-oncogenes could abrogate their post-transcriptional regulation, resulting in overexpression of oncogenic proteins, tumor initiation, progression, and modulation of drug response in cancer patients. Therefore, we developed a systematic computational pipeline that integrates data from well-established databases, followed stringent selection criteria and identified a panel of 30 high-confidence SNPs that may impair miRNA target sites in the 3' UTR of 54 mRNA transcripts of 24 proto-oncogenes. Further, 8 SNPs amidst them had the potential to determine therapeutic outcome in cancer patients. Functional annotation suggested that altogether these SNPs occur in proto-oncogenes enriched for kinase activities. We provide detailed in silico evidence for the functional effect of these candidate SNPs in various types of cancer.
authors.affiliation: Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras , Taramani Campus, Chennai, Tamil Nadu, India .
authors.forename: Mayakannan
authors.initials: M
authors.lastname: Manikandan
authors.forename: Arasambattu Kannan
authors.initials: AK
authors.lastname: Munirajan
mesh_terms: D020413:3' Untranslated Regions; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001483:Base Sequence; D001665:Binding Sites; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011494:Protein Kinases / Q000235:genetics / Q000378:metabolism; D011519:Proto-Oncogenes; D013816:Thermodynamics
chemical_list: D020413:3' Untranslated Regions; D000970:Antineoplastic Agents; D035683:MicroRNAs; D011494:Protein Kinases